UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib

Purpose To report a single case of uridine glucuronosyltransferase 1A1 (UGT1A1) polymorphism and hyperbilirubinemia in a patient who received sorafenib. Methods A 63-year-old man with cirrhosis was diagnosed with hepatocellular carcinoma. His cirrhosis was categorized as Child-Pugh A, total bilirubi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2009-12, Vol.65 (1), p.1-4
Hauptverfasser:	Meza-Junco, Judith, Chu, Quincy S.-C, Christensen, Olaf, Rajagopalan, Prabhu, Das, Soma, Stefanyschyn, Ruslan, Sawyer, Michael B
Format:	Artikel
Sprache:	eng
Schlagworte:	Alleles Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzenesulfonates - administration & dosage Benzenesulfonates - adverse effects Bilirubin Blood levels Cancer Research Carcinoma, Hepatocellular - drug therapy Cirrhosis Clinical Trials, Phase I as Topic Cyclophosphamide Cyclophosphamide - administration & dosage Doxorubicin Doxorubicin - administration & dosage Fractionation Genotyping Gilbert's syndrome Glucuronosyltransferase Glucuronosyltransferase - antagonists & inhibitors Glucuronosyltransferase - genetics Hepatocellular carcinoma Humans Hyperbilirubinemia Hyperbilirubinemia - etiology Hyperbilirubinemia - genetics Impact analysis Inhibitor drugs Liver cancer Liver cirrhosis Liver Cirrhosis - complications Liver Cirrhosis - physiopathology Liver diseases Liver Neoplasms - drug therapy Male Medicine Medicine & Public Health Middle Aged Mini Review Niacinamide - analogs & derivatives Oncology Patients Pharmacology/Toxicology Phenylurea Compounds Polymorphism Polymorphism, Genetic Pyridines - administration & dosage Pyridines - adverse effects Targeted cancer therapy Toxicity Uridine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!